Abstract Body

Background: Although recent global cost estimates indicate overall investments needed for implementation of the World Health Organization 2013 consolidated ART guidelines, detailed financial estimates for individual countries are limited. The aim of this study was to estimate additional costs for the transition of Global Fund grants to implement ART eligibility recommendations of the new guidelines.

Methods: The thirty-two countries which represent 83% of current Global Fund country allocations for HIV were included in the review. Data on treatment targets, ARV costs, and financing contributions to ARV were extracted from the Global Fund reporting database, grant documents and National AIDS Spending Assessment reports. Global projections for additional numbers of persons eligible for treatment, reported by WHO, were applied to country treatment targets to derive country-level number projections for 2015 to 2017. A weighted average ARV cost was used to determine associated ARV cost projections. Due to inter-program variability, facility and adherence support costs were not included. Treatment numbers and cost projections were disaggregated by new eligibility criteria and compared to current total allocations for HIV.

Results: ARV medicine cost for 2014 Global Fund commitments in 32 countries was estimated to be $628 million for 5 million patients on antiretroviral treatment. Additional cost of ARV medicines expected from ART eligibility recommendations was projected to be US$695 million to the end of 2017, for an additional 1.7 million persons on treatment. Costs for implementation of Option B+ and treating all HIV positive children below the age of five were US$53 million and US$106 million respectively; while initiating HIV positive persons with a CD4 count between 350 and 500 cells per mm3 and in serodiscordant relationships had estimated additional costs of US$294 million and US$242 million respectively. The total ARV medicine cost projections represented approximately 41% (US$2.6 billion) of the total HIV allocations projected from 2015 to 2017 for the 32 countries analysed.

Conclusions: ARV medicine scale up costs alone will account for a significant portion of HIV resources allocated by the Global Fund to national HIV programs. This does not take into account additional facility and adherence support costs needed for quality service delivery. Understanding differential cost data in the implementation of treatment guidelines should strengthen strategic investments and portfolio optimisation.